SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Seminars in Cardiothoracic and Vascular Anesthesia
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by O'Connor, M. F.
Right arrow Articles by Apfelbaum, J. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by O'Connor, M. F.
Right arrow Articles by Apfelbaum, J. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Update on Transfusion Therapy

Michael F. O'Connor, MD

Department of Anesthesia and Critical Care, University of Chicago, Chicago, IL

Jeffrey L. Apfelbaum, MD

Department of Anesthesia and Critical Care, University of Chicago, Chicago, IL

The science and technology of transfusion have improved dramatically over the past decade. Improvements in screen ing for viral pathogens have reduced the risk of transfusion transmitted viral infections to historic lows. Newly recog nized entities, including the transfusion transmitted virus and Parvo viruses are being investigated as pathogens. There is increasing appreciation that bacterial infection and parasites may be transmitted via transfusion, and a variety of approaches are being developed to deal with them. Clin ical studies continue to conflict about what the ideal hemo globin for patients with cardiovascular disease should be, but several studies suggest that higher hematocrits may be beneficial. Factor deficiency may play a more important role in massive transfusion than previously believed. The impor tance of autologous predeposit of red cells and hemodilu tion may diminish as the blood supply becomes ever safer, but intraoperative salvage is likely to remain an important technique. Finally, although blood substitutes have been under development for more than 10 years, they have not yet become widely used in medicine. The few remaining products under development are presently in advanced clin ical trials but face a variety of clinical and economic obsta cles before they can rise to their potential.

Seminars in Cardiothoracic and Vascular Anesthesia, Vol. 4, No. 4, 236-243 (2000)
DOI: 10.1177/108925320000400405


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement